| 英文摘要 |
Because of the abuse of extended antimicrobial agents and the increasing number of immunocompromised patients, infections caused by opportunistic pathogens, such as yeast, have increased significantly. As Candida species have become a prominent cause of nosocomial bloodstream infections, the emergence of antifungal resistance has become an important public health problem. Since antifungal susceptibilities may differ in different geographical areas and over time, surveillance reports for detection of resistance patterns are encouraged.The aim of this study was to test the antifungal susceptibilities of clinical Candida isolates, understand the resistance pattern of these pathogens and establish a database of antifungal susceptibilities to offer clinicians choices for empirical treatment when fungal infection is suspected. Our results indicate that C. albicans are susceptible to all the tested antifungal drugs. C. glabrara and C. tropicalis are more resistant to these antifungal agents than C. albicans and have different susceptibility patterns among fluconazole, itraconazole, and voriconazole. In addition, we evaluated the performance of two commercial systems, Sensititre YeastOne (Trek Diagnostic Systems) and ATB Fungus 3 (bioMérieux Clinical Diagnostics). YeastOne can provide an easy set-up procedure and reliable endpoint determinations. It is potentially useful for antifungal susceptibility testing of yeasts in clinical laboratories. |
